Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 1.00 |
| ▸ | SLC28A2 | O43868 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 1.00 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.69 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.65 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.63 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL2114452 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL360394 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL16273806 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL4455604 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2912983 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL9945547 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2056530 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2056634 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL20987631 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL8590899 | 1.00 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118255826-A | Preparation method of 4' -azidopyrimidine nucleoside and analogue thereof | 中国海洋大学 | 2024-06-28 | — | — | CN | disclosed |
| WO-2023283434-A9 | AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE BIOCONJUGATION APPROACH | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| EP-4306646-A1 | METHOD AND MEANS FOR SYNTHESIS OF C-NUCLEOSIDES OR C-NUCLEOTIDES | Technische Universität Graz (AT) | 2024-01-17 | — | — | EP | disclosed |
| WO-2024006953-A2 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230399354-A1 | PREPARATION METHOD OF 2'-SUBSTITUTED PYRIMIDINE NUCLEOSIDE | BEIJING RIBIO PHARMA CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| WO-2023224108-A1 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | 株式会社GF・Mille | 2023-11-23 | — | — | WO | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220428-A1 | COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| US-7517990-B2 | Method for deuteration of a heterocyclic ring | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20090081686-A1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| EP-1138775-B1 | Method of preparing a guanosine-group compound and an intermediate thereof | YUKI GOSEI YAKUHIN KOGYO KK (JP) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008142396-A1 | METHODS OF ASSESSING MALE FERTILITY USING A URIDINE MARKER | MAHER ANTHONY DENIS (GB) | 2008-11-27 | — | — | WO | disclosed |
| EP-1947092-A1 | NUCLEIC ACID BASE HAVING PERFLUOROALKYL GROUP AND METHOD FOR PRODUCING THE SAME | Tosoh Corporation (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-7365178-B2 | Acyl-nucleotide probes and methods of their synthesis and use in proteomic analysis | ACTIVX BIOSCIENCES, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20080064868-A1 | Novel Dideoxynucleoside Derivatives | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| CN-1044911-C | Process for preparing prodrug | IGEN INC (US) | 1999-09-01 | — | — | CN | disclosed |
| CN-1217335-A | Method for preparing precursor medicine | IGEN INC (US) | 1999-05-26 | — | — | CN | disclosed |
| CN-1070409-A | Prodrugs activated by targetted catalytic proteins | IGEN INC (US) | 1993-03-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | SLC28A1 545/4885SLC28A2 583/4885SLC29A1 216/4885 |
| US-20080064868-A1 | Novel Dideoxynucleoside Derivatives | DNA2, DDX20, DNASE1 | SLC28A1 373/4885SLC28A2 334/4885SLC29A1 150/4885 |
| US-20230399354-A1 | PREPARATION METHOD OF 2'-SUBSTITUTED PYRIMIDINE NUCLEOSIDE | UMPS, TYMP, DPYD | SLC28A1 81/4885SLC28A2 27/4885SLC29A1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.